[Congenital dysfibrinogenemia: current status and challenges in diagnosis and treatment].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Wang Z;Wang Z; Zhu TN; Zhu TN
  • Source:
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi [Zhonghua Xue Ye Xue Za Zhi] 2024 Oct 14; Vol. 45 (10), pp. 960-964.
  • Publication Type:
    Journal Article; English Abstract; Review
  • Language:
    Chinese
  • Additional Information
    • Source:
      Publisher: Chinese Medical Association Country of Publication: China NLM ID: 8212398 Publication Model: Print Cited Medium: Print ISSN: 0253-2727 (Print) Linking ISSN: 02532727 NLM ISO Abbreviation: Zhonghua Xue Ye Xue Za Zhi Subsets: MEDLINE
    • Publication Information:
      Publication: Beijing : Chinese Medical Association
      Original Publication: Beijing : Zhongguo yi xue ke xue yuan.
    • Subject Terms:
      Afibrinogenemia*/diagnosis ; Afibrinogenemia*/therapy; Humans
    • Abstract:
      Congenital dysfibrinogenemia (CDF) is the most common type of congenital fibrinogen disorders, characterized by dysfunctional fibrinogen. Its prevalence is significantly underestimated due to the absence of obvious clinical symptoms in most patients. In addition to bleeding manifestations, patients with CDF may experience thrombotic events or pregnancy-related complications. Fibrinogen antigen assays and molecular heritability analyses can help differentiate CDF from other types of congenital fibrinogen disorders. The clinical presentation of CDF varies significantly among individuals, and there is a lack of routine laboratory methods to effectively predict the risk of bleeding or thrombosis in these patients, in addition to their personal and family histories. This poses challenges in the clinical management of patients with CDF, particularly during the perioperative period or pregnancy. Further registry-based and prospective studies are needed to improve our understanding of this disease and guide clinical management.
    • References:
      BMJ Case Rep. 2017 Nov 8;2017:. (PMID: 29122898)
      Blood. 2021 Nov 25;138(21):2021-2030. (PMID: 33895794)
      Int J Mol Sci. 2018 May 29;19(6):. (PMID: 29844251)
      Thromb Res. 2010 Dec;126(6):e428-33. (PMID: 20947138)
      Curr Drug Targets. 2005 Aug;6(5):535-9. (PMID: 16026273)
      Am J Pathol. 2002 Mar;160(3):1021-34. (PMID: 11891199)
      Haemophilia. 2020 Jan;26(1):25-32. (PMID: 31709664)
      Br J Haematol. 2014 Nov;167(3):304-26. (PMID: 25100430)
      Eur J Haematol. 2019 Oct;103(4):379-384. (PMID: 31314131)
      Thromb Haemost. 2018 Feb;118(2):430-432. (PMID: 29378363)
      Thromb Res. 2012 Dec;130 Suppl 2:S7-11. (PMID: 23439004)
      Crit Care. 2019 Mar 27;23(1):98. (PMID: 30917843)
      Thromb Res. 2019 Oct;182:133-140. (PMID: 31479941)
      Blood Adv. 2024 Mar 26;8(6):1392-1404. (PMID: 38286442)
      J Thromb Haemost. 2023 Aug;21(8):2126-2136. (PMID: 37172732)
      Thromb Res. 2022 Sep;217:36-47. (PMID: 35853369)
      Blood. 2015 Jan 15;125(3):553-61. (PMID: 25320241)
      Semin Thromb Hemost. 2022 Nov;48(8):889-903. (PMID: 35073585)
      Haemophilia. 2019 Sep;25(5):747-754. (PMID: 31368232)
      J Clin Lab Anal. 2018 May;32(4):e22322. (PMID: 28922493)
      Int J Mol Sci. 2017 Dec 14;18(12):. (PMID: 29240685)
      Thromb Haemost. 2007 Jul;98(1):105-8. (PMID: 17597999)
      J Thromb Haemost. 2015 Jun;13(6):909-19. (PMID: 25816717)
      Semin Thromb Hemost. 2016 Jun;42(4):356-65. (PMID: 27019463)
      Blood. 2000 Aug 1;96(3):1191-3. (PMID: 10910944)
      Indian J Hematol Blood Transfus. 2017 Sep;33(3):431-433. (PMID: 28824252)
      J Clin Pathol. 2019 Feb;72(2):177-180. (PMID: 30463936)
      Thromb Haemost. 2018 Nov;118(11):1867-1874. (PMID: 30332696)
      Haemophilia. 2016 Sep;22(5):667-75. (PMID: 27293018)
      Thromb Haemost. 2014 Apr 1;111(4):565-6. (PMID: 24651947)
      J Thromb Haemost. 2018 Sep;16(9):1887-1890. (PMID: 30076675)
      Thromb Res. 2013 Oct;132(4):477-83. (PMID: 24041635)
      Blood Cells Mol Dis. 2015 Dec;55(4):308-15. (PMID: 26460252)
      Hamostaseologie. 2020 Nov;40(4):460-466. (PMID: 32645726)
      Biophys J. 1996 Jan;70(1):500-10. (PMID: 8770228)
      Ann N Y Acad Sci. 2001;936:89-90. (PMID: 11460527)
      J Thromb Haemost. 2015 Nov;13(11):2119-26. (PMID: 26764429)
    • Contributed Indexing:
      Local Abstract: [Publisher, Chinese] 遗传性异常纤维蛋白原血症（CDF）是以纤维蛋白原功能障碍为特点的最常见的一类先天性纤维蛋白原缺陷类型。由于多数患者无明显临床症状，导致其患病率被显著低估。除了出血表现外，CDF患者还可能合并有血栓事件或妊娠相关并发症。纤维蛋白原抗原测定以及分子遗传性分析有助于CDF与其他类型的遗传性纤维蛋白原缺陷症相鉴别。CDF患者的临床表现个体间差异显著，除了个人史及家族史外，目前尚缺乏有效预测其出血或血栓风险的常规实验室方法或手段，导致其临床管理困难，特别是围术期或妊娠期的CDF患者。未来需要更多的登记组研究和前瞻性研究以提高对该疾病的认识和指导患者的临床管理。.
    • Subject Terms:
      Dysfibrinogenemia, Congenital
    • Publication Date:
      Date Created: 20241202 Date Completed: 20241202 Latest Revision: 20241211
    • Publication Date:
      20241212
    • Accession Number:
      PMC11579749
    • Accession Number:
      10.3760/cma.j.cn121090-20240326-00115
    • Accession Number:
      39622762